Nf-kb gene signature predicts prostate cancer progression

Cancer Research

Volumn 74, Issue 10, 2014, Pages 2763-2772

  Jin, Renjie ^a   Yi, Yajun ^b   Yull, Fiona E ^b   Blackwell, Timothy S ^b   Clark, Peter E ^a   Koyama, Tatsuki ^b   Smith Jr , Joseph A ^a   Matusik, Robert J ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; GENE; GENE ACTIVATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MALE; MOUSE; NARP21 GENE; NF KB GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; ANIMAL; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; I-KAPPA B PROTEINS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NF-KAPPA B; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION;

EID: 84901255009     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2543     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. New Engl J Med 2009;360:1310-9.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. New Engl J Med 2012;366:981-90.
4. Moyer VA. Screening for prostate cancer:U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.
5. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005;93: 1019-23.
6. Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, et al. Nuclear localization of nuclear factorkappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006;12:5741-5.
7. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, et al. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005;93:1285-94.
8. Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006;12:5578-86.
9. Ismail HA, Lessard L, Mes-Masson AM, Saad F. Expression of NFkappaB in prostate cancer lymph node metastases. Prostate 2004; 58:308-13.
10. Ross JS, Kallakury BV, Sheehan CE, FisherHA, KaufmanRPJr., Kaur P, et al. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factorkappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004;10:2466-72.
11. Setlur SR, Royce TE, Sboner A, Mosquera JM,Demichelis F, Hofer MD, et al. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 2007;67:10296-303.
12. McCall P, Bennett L, Ahmad I, Mackenzie LM, Forbes IW, Leung HY, et al. NFkappaB signalling is upregulated in a subset of castrateresistant prostate cancer patients and correlates with disease progression. Br J Cancer 2012;107:1554-63.
13. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008;68:6762-9.
14. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, et al. NFkappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009;175:489-99.
15. Inoue J, Gohda J, Akiyama T, Semba K. NF-kappaB activation in development and progression of cancer. Cancer Sci 2007;98:268-74.
16. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6.
17. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors 2007;29:19-35.
18. Jin R, Sterling JA, Edwards JR, DeGraff DJ, Lee C, Park SI, et al. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone. PloS ONE 2013;8:e60983.
19. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212-21.
20. Chen CL, Singh N, Yull FE, Strayhorn D, Van Kaer L, Kerr LD. Lymphocytes lacking I kappa B-Alpha develop normally, but have selective defects in proliferation and function. J Immunol 2000;165: 5418-27.
21. Chen CL, Yull FE, Cardwell N, Singh N, Strayhorn WD, Nanney LB, et al. RAG2+/-, I kappa B-Alpha+/-chimeras display a psoriasiform skin disease. J Invest Dermatol 2000;115:1124-33.
22. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
23. GSE10645. Available from: http://www.ncbi.nlm.nih.gov/geo.
24. Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS ONE 2008;3:e2318.
25. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
26. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003;34:374-8.
27. Wu J, Qiu Q, Xie L, Fullerton J, Yu J, Shyr Y, et al. Web-based interrogation of gene expression signatures using EXALT. BMC Bioinformatics 2009;10:420.
28. Lukes L, Crawford NP, Walker R, Hunter KW. The origins of breast cancer prognostic gene expression profiles. Cancer Res 2009;69: 310-8.
29. Diessenbacher P, Hupe M, Sprick MR, Kerstan A, Geserick P, Haas TL, et al. NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J Invest Dermatol 2008;128:1134-47.
30. Levenberg S, Huang NF, Lavik E, Rogers AB, Itskovitz-Eldor J, Langer R. Differentiation of human embryonic stem cells on three-dimensional polymer scaffolds. Proc Natl Acad Sci U S A 2003;100:12741-6.
31. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
32. Kretzschmar M, Meisterernst M, Scheidereit C, Li G, Roeder RG. Transcriptional regulation of the HIV-1 promoter by NF-kappa B in vitro. Genes Dev 1992;6:761-74.
33. Everhart MB, Han W, Sherrill TP, Arutiunov M, Polosukhin VV, Burke JR, et al. Duration and intensity of NF-{kappa}B activity determine the severity of endotoxin-induced acute lung injury. J Immunol 2006; 176:4995-5005.
34. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
35. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53-And IGF-independent mechanism. J Biol Chem 1997;272:12181-8.
36. Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet 1998;62:653-8.
37. Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. Horm Metab Res 1994;26:81-4.
38. Klotz L, Zhang L, Lam A,NamR,Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
39. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004;113:913-23.
40. Markert EK, Mizuno H, Vazquez A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 2011;108:21276-81.
41. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-73.
42. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489-95.
43. Hubner A, Mulholland DJ, Standen CL, Karasarides M, Cavanagh-Kyros J, Barrett T, et al. JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A 2012;109:12046-51.